We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$98.4M
Cap. Flow %
8.63%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Avg Time Held Equity + Options
3 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.2 quarters
Avg Time Held Equity only
3.1 quarters
Top 10 Avg Time Held Equity only
4.1 quarters
Top 20 Avg Time Held Equity only
4.3 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO icon
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Miscellaneous 6.35%
3 Consumer Staples 0.6%
4 Consumer Discretionary 0.11%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TARO icon
126
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$491K 0.04%
3,429
+1,936
+130% +$275K
2013 Q4
9 quarters
GNVC
127
DELISTED
GenVec, Inc.
GNVC
$489K 0.04%
60,664
-920
-1% -$6.17K
2014 Q1
8 quarters
SYNH
128
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$488K 0.04%
+11,846
New +$488K
2016 Q1
0 quarters
CAH icon
129
Cardinal Health
CAH
$55.5B
$487K 0.04%
+5,947
New +$484K
2016 Q1
0 quarters
AFAM
130
DELISTED
Almost Family Inc
AFAM
$487K 0.04%
13,075
+8,186
+167% +$306K
2015 Q4
1 quarter
IQV icon
131
IQVIA
IQV
$42.9B
$485K 0.04%
7,447
+4,749
+176% +$300K
2015 Q4
1 quarter
CRL icon
132
Charles River Laboratories
CRL
$14.3B
$474K 0.04%
6,244
+2,834
+83% +$210K
2015 Q4
1 quarter
MACK icon
133
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$419K 0.04%
6,355
– –
2015 Q4
1 quarter
PMC
134
DELISTED
PharMerica Corporation
PMC
$372K 0.03%
16,841
+10,041
+148% +$267K
2015 Q2
3 quarters
EOCN icon
135
Eocene Ltd. Ordinary Shares
EOCN
$3.38M
$369K 0.03%
52
– –
2014 Q1
8 quarters
STML
136
DELISTED
Stemline Therapeutics, Inc.
STML
$366K 0.03%
78,603
– –
2015 Q1
4 quarters
GRCE icon
137
Grace Therapeutics
GRCE
$41.9M
$360K 0.03%
4,928
– –
2013 Q3
10 quarters
SPY icon
138
State Street SPDR S&P 500 ETF Trust
SPY
$822B
$329K 0.03%
+1,600
New +$312K
2016 Q1
0 quarters
ARMP icon
139
Armata Pharmaceuticals
ARMP
$115M
$315K 0.03%
571
+37
+7% +$19K
2015 Q3
2 quarters
CNC icon
140
Centene
CNC
$34B
$305K 0.03%
9,896
+4,710
+91% +$141K
2015 Q4
1 quarter
TRIL
141
DELISTED
Trillium Therapeutics Inc.
TRIL
$278K 0.02%
30,000
– –
2015 Q2
3 quarters
APYX icon
142
Apyx Medical
APYX
$110M
$272K 0.02%
162,700
– –
2015 Q1
4 quarters
IMUX icon
143
Immunic
IMUX
$94M
$271K 0.02%
+75
New +$261K
2016 Q1
0 quarters
DRNA
144
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$268K 0.02%
50,000
– –
2015 Q2
3 quarters
GTS
145
DELISTED
Triple-S Management Corporation
GTS
$264K 0.02%
11,147
– –
2014 Q2
7 quarters
RACE icon
146
Ferrari
RACE
$68.7B
$259K 0.02%
+6,200
New +$250K
2016 Q1
0 quarters
TNDM icon
147
Tandem Diabetes Care
TNDM
$1.16B
$217K 0.02%
2,500
– –
2015 Q4
1 quarter
ELGX
148
DELISTED
Endologix Inc
ELGX
$209K 0.02%
2,500
-27,500
-92% -$2.27M
2014 Q4
5 quarters
AKAO
149
DELISTED
Achaogen Inc
AKAO
$166K 0.01%
60,000
– –
2014 Q1
8 quarters
MNK
150
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$164K 0.01%
+2,673
New +$171K
2016 Q1
0 quarters
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $98.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.